Akari Therapeutics Plc (AKTX)


Stock Price Forecast

May 22, 2020


Forecasted Returns

7 Days Predict

30 Days Predict

90 Days Predict


Forecasted Market-Excess Returns

7 Days Predict

30 Days Predict

90 Days Predict

Loading Akari Therapeutics Plc chart...

About the Company

Akari Therapeutics Plc is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of therapeutics to treat orphan autoimmune and inflammatory diseases. Its lead product candidate, Nomacopan, is a second-generation complement inhibitor. The company was founded on October 7, 2004 and is headquartered in London, the United Kingdom.

Sector

Health Technology

Industry

Pharmaceuticals: Major

Employees

10

CEO

Clive Stuart Richardson

Exchange

NASDAQ

Website

http://akaritx.com

$M

Total Revenue

10

Employees

$36M

Market Capitalization

-2.01

Price/Earning ratio

Fundamental Data and Insider Transactions (Quarterly data) Full Screen

Loading the fundamentals chart...

Latest $AKTX News

Akari Therapeutics enters merger deal with Peak Bio

12d ago, source: Pharmaceutical Technology on MSN

Akari Therapeutics has signed an agreement with Peak Bio to merge in an all-stock transaction, creating a diversified ...

Akari Therapeutics, Peak Bio Announces Agreement To Merge As Equals - Quick Facts

13d ago, source:

Akari Therapeutics, Plc (AKTX) and Peak Bio Inc. announced a definitive agreement to merge as equals in an all-stock deal. The ...

Akari Therapeutics Plc Sponsored ADR

2mon ago, source: CNN

Akari Therapeutics Plc is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of therapeutics to treat orphan autoimmune and inflammatory diseases.

Akari Therapeutics PLC (AKTX)

6d ago, source: Investing

Akari Therapeutics, Plc (NASDAQ:AKTX) announced that the FDA has granted an orphan drug designation to its lead pipeline candidate nomacopan for the treatment of bullous ...

AKTX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Akari Therapeutics, Plc Is Fair to Shareholders

13d ago, source: Stockhouse

Halper Sadeh LLC, an investor rights law firm, is investigating whether the merger of Akari Therapeutics, Plc (NASDAQ: AKTX) and Peak Bio Inc. is fair to Akari shareholders. The investigation concerns ...

Akari Therapeutics PLC (CLA.BE)

1mon ago, source: Yahoo Finance

*Close price adjusted for splits.**Close price adjusted for splits and dividend and/or capital gain distributions. Loading more data ...

Akari Therapeutics PLC ADR

1mon ago, source: Wall Street Journal

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Akari Therapeutics, Plc (AKTX)

2y ago, source: Yahoo Finance

For example, although Amazon.com... Simply Wall St. Insiders rewarded with a US$607k addition on top of their US$1.3m purchase as Akari Therapeutics, Plc (NASDAQ:AKTX) hits US$22m Last week, Akari ...

Akari Therapeutics, Plc (AKTX)

1mon ago, source: Yahoo Finance

*Close price adjusted for splits.**Close price adjusted for splits and dividend and/or capital gain distributions. Loading more data ...

Latest Neutral (free) Forecasts

STRONG BUY BUY NEUTRAL SELL STRONG SELL ALL

Loading the latest forecasts...

My Portfolio

Loading your portfolio...